Recently, Wang et al. [126] reported that the viabilities of prostate cancer cells increased upon treatment with conditioned media from EREG-overexpressing prostate stromal cells and that treatment with an anti-EREG monoclonal antibody reduced this effect. This evidence concerns the gene EREG and Familial prostate cancer.